Los Angeles Capital Management
NKTR icon

Los Angeles Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Los Angeles Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.87K Hold
127
– – ﹤0.01% 1994
2026
Q1 		$9.14K Hold
127
– – ﹤0.01% 1977
2025
Q4 		$7.98K Buy
+127
New +$7.11K ﹤0.01% 2156
2018
Q3 		– Sell
-5,488
Closed -$4.02M – 1454
2018
Q2 		$4.02M Sell
5,488
-375
-6% -$432K 0.02% 528
2018
Q1 		$9.35M Buy
5,863
+3,258
+125% +$4.2M 0.05% 330
2017
Q4 		$2.33M Buy
2,605
+1,782
+217% +$1.05M 0.01% 629
2017
Q3 		$296K Buy
+823
New +$257K ﹤0.01% 1153
2016
Q4 		– Sell
-742
Closed -$191K – 1212
2016
Q3 		$191K Sell
742
-261
-26% -$67.2K ﹤0.01% 1170
2016
Q2 		$214K Buy
+1,003
New +$224K ﹤0.01% 1141
2014
Q2 		– Sell
-1,388
Closed -$252K – 1260
2014
Q1 		$252K Buy
1,388
+664
+92% +$131K ﹤0.01% 1119
2013
Q4 		$123K Sell
724
-2,158
-75% -$348K ﹤0.01% 1246
2013
Q3 		$451K Sell
2,882
-50
-2% -$9.24K 0.01% 953
2013
Q2 		$508K Buy
+2,932
New +$450K 0.01% 904

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Los Angeles Capital Management's NKTR Position: Q2 2026 in Review

Los Angeles Capital Management held its Nektar Therapeutics (NKTR) position steady in Q2 2026 at 127 shares worth $8.87K. The position accounts for ﹤0.01% of the portfolio, ranked #1994.

Los Angeles Capital Management first reported a position in NKTR in Q2 2013 and has held it in 13 quarters since. The position peaked at $9.35M in Q1 2018. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Los Angeles Capital Management held 127 shares of Nektar Therapeutics worth $8.87K as of Q2 2026.
  • Los Angeles Capital Management left its Nektar Therapeutics share count unchanged in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1994 holding.
  • Los Angeles Capital Management first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 13 quarters since.
  • Los Angeles Capital Management's Nektar Therapeutics position peaked at $9.35M in Q1 2018.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.